Madhuri Vusirikala, M.D. is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology-Oncology. She is Medical Director of the Adult National Marrow Donor Program Transplant Program at UT Southwestern, as well as Director of the Allogeneic Stem Cell Transplant Program, and Director of the Inpatient Bone Marrow Transplant Unit.
Dr. Vusirikala received her medical degree from Lady Hardinge Medical College in New Delhi, India, and completed internal medicine residency training at the State University of New York in Syracuse. She then completed advanced training through a fellowship in hematology/oncology at the University of Pittsburgh, and a subsequent fellowship in bone marrow transplant at Vanderbilt University Medical Center.
Certified by the American Board of Internal Medicine in internal medicine, oncology, and hematology, she served on the faculty of Vanderbilt University School of Medicine before joining the UT Southwestern faculty in 2006.
Dr. Vusirikala’s research interests include graft-versus-host disease, malignant hematologic disorders, and survivorship after stem cell transplant.
Her investigations have resulted in many publications in peer-reviewed journals. Additionally, she has presented her findings at scientific conferences throughout the United States and the world.
Dr. Vusirikala is active in several professional societies, including the Texas Medical Association, the Dallas County Medical Society, the American Society of Transplantation and Cellular Therapy, and the American College of Physicians.
- Medical School
- Lady Hardinge Medical College, India (1991)
- Delhi University/Maulana Azad Medical College (1993), Internal Medicine
- SUNY Upstate Medical University (1996), Internal Medicine
- University of Pittsburgh (1999), Hematology Oncology
- Advanced Fellowship
- Vanderbilt University Medical Center (2000), Bone Marrow Transplant
- acute and chronic graft versus host disease
- acute leukemias
- allogeneic stem cell transplant in hematologic disorders
- Other malignant hematologic disorders-lymphomas, MDS, MPD, MF, myeloma
- survivorship after stem cell transplant
- Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials.
- Schlenk R, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, Spencer A, Candoni A, Sierra Gil J, Berkowitz N, Weber HJ, Ottmann O Haematologica 2017 Oct
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
- Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB J. Clin. Oncol. 2017 Oct JCO2017758177
- Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation.
- Brown TJ, Gentry C, Hammer ST, Hwang CS, Vusirikala M, Patel PA, Matevosyan K, Tujios SR, Mufti AR, Collins RH ACG Case Rep J 2017 4 e48
- PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.
- Salahudeen AA, Gupta A, Jones JC, Cowan RW, Vusirikala M, Kwong C, Naina HV Clin Lymphoma Myeloma Leuk 2015 Jun
- Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
- Naina HV, Levitt D, Vusirikala M, Anderson LD, Scaglioni PP, Kirk A, Collins RH J. Clin. Oncol. 2011 Jun 29 18 e534-6
- Hematogone hyperplasia in copper deficiency.
- Sutton L, Vusirikala M, Chen W Am. J. Clin. Pathol. 2009 Aug 132 2 191-9; quiz 307
- Valacyclovir for the prevention of cytometalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
- Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA Bone Marrow Transplant August 2001 28 265-70
- Dose-Intensification and Stem Cell Transplantation (SCT) for histologically transformed Low-grade Follicular Non-Hodgkin Lymphoma (NHL): A single center experience
- Vusirikala M, Brandt S, Chinratanalab W, Greer JP, Jagasia M, Kassim A, Mineshi S, Morgan DS, Ruffner K, Friedrich SG, Shyr Y, Goodman SA Biol Blood Marrow Transplant 2004 10 192
- A phase II trial of high dose chemotherapy and conccurrent rituximab followed by autologous peripheral blood stem cell transplantation for treatment of relapsed CD20 positive B-cell Non-Hodgkin’s Lymphoma
- Vusirikala M, Stein RS, Brandt S, Morgan D, Greer J, Jagasia M, Kassim A, Schuening F, Goodman S Biol Blood Marrow Transplant 2002 8 101
Supportive Care in Hematologic Malignancies. In Wintrobe's Clinical Hematology, 12th edition.
Vusirikala, Madhuri (2009). Philadelphia, Lippincott Williams & Wilkins
Supportive Care in Hematologic Malignancies. In Wintrobe's Clinical Hematology, 11th edition.
Vusirikala, Madhuri (2003). Philadelphia, Lippincott Williams & Wilkins
- American Society of Bone Marrow Transplant (2010)
- American Society of Hematology (1998)